The Shift Toward Earlier, Lower-Burden On-Demand Treatment in Hereditary Angioedema

Key Takeaways:

• Guideline consensus holds that every patient with hereditary angioedema (HAE) should have ready access to effective on-demand therapy and should treat attacks as early as possible, regardless of the site of swelling.
• On-demand options span 3 mechanism-based classes – C1 esterase inhibitor (C1-INH) replacement, bradykinin B2 receptor antagonism, and plasma kallikrein inhibition – that differ meaningfully in route of administration.
• Because earlier treatment is associated with shorter, less severe attacks, time-to-treatment and the practical burden of administration are clinical variables, not logistical afterthoughts.

On-demand therapy is the foundation of HAE management. The US Hereditary Angioedema Association Medical Advisory Board frames acute care around 4 guiding principles:¹

• Availability of effective on-demand therapy for every patient
• Early treatment to stop progression
• Treatment of all attacks irrespective of location
• Individualized long-term prophylactic treatment incorporated through physician-patient decision-making

The first 3 of those principles speak directly to how a clinician equips a patient to handle the next unpredictable attack, and recent changes in the treatment landscape have widened the options for doing so.

Why early treatment changes outcomes

Bradykinin-mediated attacks progress over hours, and the swelling present when treatment is given still takes time to resolve. The clinical leverage point is arresting progression early. Guidelines therefore advise patients to carry enough on-demand medication for at least 2 attacks and to treat as soon as an attack is clearly recognized rather than waiting to gauge severity.^1,2

In the phase 3 crossover trial of an oral plasma kallikrein inhibitor, the median time from attack onset to treatment was 41 minutes, and 43 percent of treated attacks were still mild at the time of treatment, a pattern of early self-treatment that contrasts with the longer delays documented for parenteral agents in observational studies.³

Even at that median, the majority of treated attacks had already progressed to moderate or greater severity, which reinforces the case for treating as early as possible. Earlier administration has consistently been associated with shorter attacks and faster symptom relief.^1,3

On-demand options by mechanism and route

Three mechanism-based classes are used for acute attacks. C1-INH replacement restores the deficient or dysfunctional inhibitor and is administered intravenously. The bradykinin B2 receptor antagonist blocks bradykinin at its receptor and is given subcutaneously. Plasma kallikrein inhibitors act upstream, reducing bradykinin generation; this class includes 2 intravenous agents, a subcutaneous agent that, because of a small risk of anaphylaxis, is administered by a healthcare provider, and, more recently, an oral agent.^1,3

Each first-line on-demand option has shown efficacy and an acceptable safety profile in randomized trials, and the choice among them is individualized to the patient. Treatment-safety considerations belong in that conversation: Any attack involving the larynx, tongue, or throat carries a real mortality risk, and patients should seek emergency care even after self-treating an airway attack.¹

Treatment burden as a clinical variable

Until recently, every first-line on-demand option required injection or infusion – a route of administration associated with delays in treatment or withholding of therapy. The effort to transport, store, and prepare a parenteral medication, hesitation about self-injection, and the need in some cases to travel to a clinic all push treatment later into the attack, working against the early-treatment principle.³

Viewing route and time-to-administration as clinical variables, rather than logistics, reframes on-demand planning: The goal is a regimen the individual patient will actually use early and reliably. That burden is not abstract. In a 2020 US survey, patients with HAE reported high rates of anxiety and quality-of-life impairment that worsened with attack frequency, underscoring the value of a dependable, low-friction on-demand plan.⁴

Practically, every patient – regardless of whether they take a long-term prophylaxis – needs an effective on-demand option, a written action plan, and clear guidance on treating early and escalating airway attacks to emergency care.¹